Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential As A Precision Medicine For Cancer
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE